We had the pleasure of exhibiting at the 25th Annual International AF Symposium which took place on January 23-25, 2020, in Washington, DC. This intensive three-day symposium brought together the world’s leading medical scientists to share — in a highly interactive environment — the most recent advances in the field of atrial fibrillation.
We were impressed with the interest in new technologies we saw during the event. We presented alongside some of the most prestigious companies, accomplished doctors, scientists, medical experts, executives, and leaders in the healthcare industry. It was an honor to have the ability to witness groundbreaking scientific discussions, speak with exhibitors, exchange ideas with individuals that care so about people that suffer from this debilitating disease, and educate the audience about the advancements and progress that BioSig was making in the field.
Some of the noteworthy participating companies included Medtronic [NYSE: MDT], Abbot [NYSE: ABT], Biosense Webster [NYSE: JNJ], Boston Scientific [NYSE: BSX], Bristol-Myers Squibb [NYSE: BMY], Philips [NYSE: PHG] and many others.The BioSig team showed up strong with executive leadership, clinical, commercial, and engineering teams in attendance. BioSig was in the first Spotlight session at the Symposium, Early Stage and Emerging New Technologies and Drugs in Cardiac EP, during which the PURE EP™ System was presented by Andrea Natale, M.D., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. As a result of our presentation, we saw significant interest from various medical institutions across the country that are interested in learning more about PURE EP™ System.
Dr. Natale has been involved with our technology since its very early days and has performed our first-in-human study in February 2019 and our clinical trial that was initiated at Texas Cardiac Arrhythmia Institute (TCAI) under his leadership in November 2019, making him the most equipped to walk through the system in the clinical setting. During his presentation, Dr. Natale talked about the value proposition of PURE EP™ and how it differentiated from other systems in the market. Lastly, he talked in more detail about the clinical observations collected during the trial so far and presented a range of signal comparisons that showed new clinical information TCAI physician team were able to see via PURE EP™ vs. other systems.
Some of the other highlights from the event included:
- Providing over 40 product demonstrations over the course of the symposium, which spoke to the interest we received
- Hosting a private, invitation-only event with investors during which they had a chance to receive business updates from our leadership team and meet with BioSig’s Board of Directors.
An interesting key takeaway from the event was that many key opinion leaders (KOLs) were making references and inferences that the industry was going back to fundamentals, emphasizing the importance of signal quality. This takeaway is of great importance to us, as signal clarity is one of the main benefits and core features to our PURE EP™ System.
Although the AFib market is vast in terms of dollars, so are the number of patients that suffer. We believe in the PURE EP™ System and the help it can provide to people, and the feedback we received at the AF Symposium 2020 adds to the momentum we are carrying.
Kenneth L. Londoner
Chairman and CEO
BioSig Technologies, Inc.